The ubiquitin proteasome system as a potential target for the treatment of neurodegenerative diseases

Current Pharmaceutical Design

Volumn 19, Issue 18, 2013, Pages 3305-3314

  Ying, Zheng ^a   Wang, Hongfeng ^a   Wang, Guanghui ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Deubiquitination; Parkinson's disease; Ubiquitin proteasome system

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ATAXIN 3; CLIOQUINOL; HEAT SHOCK PROTEIN; PARKIN; PROTEASOME; PROTEIN P53; SUPEROXIDE DISMUTASE; TAR DNA BINDING PROTEIN; TAU PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; BINDING SITE; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CHROMOSOME 17; COMPETITIVE INHIBITION; CONJUGATION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; UBIQUITINATION;

ANIMALS; CELL DEATH; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84878820361     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319180013     Document Type: Review

References (138)

1. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins inneurodegenerative disease. Science 2002; 296: 1991-5.
2. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. JCell Mol Med 2008; 12: 363-73.
3. Weissman AM. Themes and variations on ubiquitylation. Nat RevMol Cell Biol 2001; 2: 169-78.
4. Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. NatRev Mol Cell Biol 2009; 10: 755-64.
5. Adhikari A, Chen ZJ. Diversity of polyubiquitin chains. Dev Cell 2009; 16: 485-6.
6. Xu P, Duong DM, Seyfried NT, et al. Quantitative proteomicsreveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009; 137: 133-45.
7. Smalle J, Vierstra RD. The ubiquitin 26S proteasome proteolyticpathway. Annu Rev Plant Biol 2004; 55: 555-90.
8. Pickart CM. Mechanisms underlying ubiquitination. Annu RevBiochem 2001; 70: 503-33.
9. van Wijk SJ, Timmers HT. The family of ubiquitin-conjugatingenzymes (E2s): deciding between life and death of proteins. FASEB J, 2010; 24: 981-93.
10. Jin J, Li X, Gygi SP, Harper JW. Dual E1 activation systems forubiquitin differentially regulate E2 enzyme charging. Nature 2007; 447: 1135-8.
11. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399-434.
12. Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic andfunctional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-86.
13. Kohler A, Schneider M, Cabal GG, Nehrbass U, Hurt E. YeastAtaxin-7 links histone deubiquitination with gene gating and mRNA export. Nat Cell Biol 2008; 10: 707-15.
14. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATRsubstrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-6.
15. Schmidt M, Hanna J, Elsasser S, Finley D. Proteasome-associatedproteins: regulation of a proteolytic machine. Biol Chem 2005; 386: 725-37.
16. Song L, Rape M. Reverse the curse--the role of deubiquitination incell cycle control. Curr Opin Cell Biol 2008; 20: 156-63.
17. Zhu P, Zhou W, Wang J, et al. A histone H2A deubiquitinasecomplex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol Cell 2007; 27: 609-21.
18. Wang Q, Li L, Ye Y. Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3. J Cell Biol 2006; 174: 963-71.
19. Balut CM, Loch CM, Devor DC. Role of ubiquitylation and USP8-dependent deubiquitylation in the endocytosis and lysosomal targeting of plasma membrane KCa3.1. FASEB J 2011; 25: 3938-48.
20. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the humandeubiquitinating enzyme interaction landscape. Cell 2009; 138: 389-403.
21. Pickart CM, Fushman D. Polyubiquitin chains: polymeric proteinsignals. Curr Opin Chem Biol 2004; 8: 610-6.
22. Wang H, Ying Z, Wang G. Ataxin-3 Regulates AggresomeFormation of Copper-Zinc Superoxide Dismutase (SOD1) by Editing K63-linked Polyubiquitin Chains. J Biol Chem 2012; 287: 28576-85.
23. Olzmann JA, Li L, Chudaev MV, et al. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 2007; 178: 1025-38.
24. Newton K, Matsumoto ML, Wertz IE, et al. Ubiquitin chain editingrevealed by polyubiquitin linkage-specific antibodies. Cell 2008; 134: 668-78.
25. Dennissen FJ, Kholod N, van Leeuwen FW. The ubiquitinproteasome system in neurodegenerative diseases: culprit, accomplice or victim? Prog Neurobiol 2012; 96: 190-207.
26. Yang WL, Wang J, Chan CH, et al. The E3 ligase TRAF6 regulatesAkt ubiquitination and activation. Science 2009; 325: 1134-8.
27. Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9Xstabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-7.
28. Angeles A, Fung G, Luo H. Immune and non-immune functions ofthe immunoproteasome. Front Biosci 2012; 17: 1904-16.
29. Hofmann RM, Pickart CM. In vitro assembly and recognition ofLys-63 polyubiquitin chains. J Biol Chem, 2001; 276: 27936-43.
30. Schlossarek S, Carrier L. The ubiquitin-proteasome system incardiomyopathies. Curr Opin Cardiol 2011; 26: 190-5.
31. Li YF, Wang X. The role of the proteasome in heart disease. Biochim Biophys Acta 2011; 1809: 141-9.
32. Wang X, Li J, Zheng H, Su H, Powell SR. Proteasome functionalinsufficiency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol 2011; 301: H2207-19.
33. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL,Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-9.
34. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev, 2001; 81: 741-66.
35. Ross CA, Poirier MA. Opinion: What is the role of proteinaggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005; 6: 891-8.
36. Williams AJ, Paulson HL. Polyglutamine neurodegeneration:protein misfolding revisited. Trends Neurosci 2008; 31: 521-8.
37. Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W. Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J 2004; 18: 1571-3.
38. Bergman A, Hansson EM, Pursglove SE, et al. Pen-2 is sequesteredin the endoplasmic reticulum and subjected to ubiquitylation and proteasome-mediated degradation in the absence of presenilin. J Biol Chem 2004; 279: 16744-53.
39. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of pairedhelical filaments in Alzheimer's disease. Science 1987; 235: 1641-4.
40. Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected inneurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 1987; 84: 3033-6.
41. Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer TA. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol 2006; 111: 312-9.
42. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem, 2006; 281: 10825-38.
43. Perry G, Stewart D, Friedman R, Manetto V, Autilio-Gambetti L, Gambetti P. Filaments of Pick's bodies contain altered cytoskeletal elements. Am J Pathol 1987; 127: 559-68.
44. Murayama S, Mori H, Ihara Y, Tomonaga M. Immunocy-tochemical and ultrastructural studies of Pick's disease. Ann Neurol 1990; 27: 394-405.
45. Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994; 55: 1159-65.
46. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked tochromosome 17: a consensus conference. Conference Participants. Ann Neurol 1997; 41: 706-15.
47. Paulus W, Selim M. Corticonigral degeneration with neuronalachromasia and basal neurofibrillary tangles. Acta Neuropathol 1990; 81: 89-94.
48. Auer IA, Schmidt ML, Lee VM, et al. Paired helical filament tau(PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol 1995; 90: 547-51.
49. Keller JN, Hanni KB, Markesbery WR. Impaired proteasomefunction in Alzheimer's disease. J Neurochem 2000; 75: 436-9.
50. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition bypaired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003; 85: 115-22.
51. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 1995; 270: 19702-8.
52. Lopez Salon M, Morelli L, Castano EM, Soto EF, Pasquini JM. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 2000; 62: 302-10.
53. Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A geneexpression profile of Alzheimer's disease. DNA Cell Biol 2001; 20: 683-95.
54. van Leeuwen FW, de Kleijn DP, van den Hurk HH, et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-7.
55. Fischer DF, De Vos RA, Van Dijk R, et al. Disease-specificaccumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J 2003; 17: 2014-24.
56. Lindsten K, de Vrij FM, Verhoef LG, et al. Mutant ubiquitin foundin neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol, 2002; 157: 417-27.
57. Song S, Kim SY, Hong YM, et al. Essential role of E2-25K/Hip-2in mediating amyloid-beta neurotoxicity. Mol Cell 2003; 12: 553-63.
58. Choi J, Levey AI, Weintraub ST, et al. Oxidative modifications anddown-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004; 279: 13256-64.
59. Barrachina M, Castano E, Dalfo E, Maes T, Buesa C, Ferrer I.Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiol Dis 2006; 22: 265-73.
60. Gong B, Cao Z, Zheng P, et al. Ubiquitin hydrolase Uch-L1rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006; 126: 775-88.
61. Ichihara N, Wu J, Chui DH, Yamazaki K, Wakabayashi T, Kikuchi T. Axonal degeneration promotes abnormal accumulation of amyloid beta-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse. Brain Res 1995; 695: 173-8.
62. Xue S, Jia J. Genetic association between Ubiquitin Carboxy-terminal Hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population. Brain Res 2006; 1087: 28-32.
63. Zhang M, Deng Y, Luo Y, et al. Control of BACE1 degradationand APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem 2012; 120: 1129-38.
64. Dennissen FJ, Kholod N, Hermes DJ, et al. Mutant ubiquitin(UBB+1) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3). FEBS Let, 2011; 585: 2568-74.
65. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-bodyformation is an aggresome-related process: a hypothesis. Lancet Neurol 2004; 3: 496-503.
66. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in thealpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
67. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the geneencoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-8.
68. Singleton AB, Farrer M, Johnson J, et al. Alpha-Synuclein locustriplication causes Parkinson's disease. Science 2003; 302: 841.
69. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167-9.
70. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation,E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-73.
71. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003; 278: 44405-11.
72. Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-Synuclein isphosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-4.
73. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation ofSer-129 is the dominant pathological modification of alpha synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281: 29739-52.
74. Liu C, Fei E, Jia N, et al. Assembly of lysine 63-linked ubiquitinconjugates by phosphorylated alpha-synuclein implies Lewy body biogenesis. J Biol Chem 2007; 282: 14558-66.
75. Smith WW, Margolis RL, Li X, et al. Alpha-synucleinphosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 2005; 25: 5544-52.
76. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003; 179: 38-46.
77. McNaught KS, Jenner P. Proteasomal function is impaired insubstantia nigra in Parkinson's disease. Neurosci Lett 2001; 297: 191-4.
78. Furukawa Y, Vigouroux S, Wong H, et al. Brain proteasomalfunction in sporadic Parkinson's disease and related disorders. Ann Neurol 2002; 51: 779-82.
79. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemicexposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004; 56: 149-62.
80. Bedford L, Hay D, Devoy A, et al. Depletion of 26S proteasomesin mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008; 28: 8189-98.
81. Wang XF, Li S, Chou AP, Bronstein JM. Inhibitory effects ofpesticides on proteasome activity: implication in Parkinson's disease. Neurobiol Dis 2006; 23: 198-205.
82. Fornai F, Schluter OM, Lenzi P, et al. Parkinson-like syndromeinduced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005; 102: 3413-8.
83. Mandel S, Grunblatt E, Riederer P, et al. Gene expression profilingof sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 2005; 1053: 356-75.
84. Fishman-Jacob T, Reznichenko L, Youdim MB, Mandel SA. Asporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A. J Biol Chem 2009; 284: 32835-45.
85. Mandel SA, Fishman-Jacob T, Youdim MB. Genetic reduction ofthe E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease. Parkinsonism Relat Disord 2012; 18 Suppl 1: S177-9.
86. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996; 381: 571-9.
87. McLean PJ, Kawamata H, Shariff S, et al. TorsinA and heat shockproteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 2002; 83: 846-54.
88. Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA. UCH-L1aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 2004; 90: 379-91.
89. Li HM, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. Association ofDJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress. Free Radic Res 2005; 39: 1091-9.
90. de la Monte SM, Sohn YK, Wands JR. Correlates of p53-and Fas(CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 1997; 152: 73-83.
91. Hartmann A, Michel PP, Troadec JD, et al. Is Bax a mitochondrialmediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem 2001; 76: 1785-93.
92. Blum D, Wu Y, Nissou MF, Arnaud S, Alim Louis B, Verna JM. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Res 1997; 751: 139-42.
93. Duan W, Zhu X, Ladenheim B, et al. p53 inhibitors preservedopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52: 597-606.
94. Fan J, Ren H, Jia N, et al. DJ-1 decreases Bax expression throughrepressing p53 transcriptional activity. J Biol Chem 2008; 283: 4022-30.
95. da Costa CA, Sunyach C, Giaime E, et al. Transcriptionalrepression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009; 11: 1370-5.
96. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin genecause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
97. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. Anunfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001; 105: 891-902.
98. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruitedselectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183: 795-803.
99. Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediatedmitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010; 12: 119-31.
100. Da Cruz S, Cleveland DW. Understanding the role of TDP-43 andFUS/TLS in ALS and beyond. Curr Opin Neurobiol 2011; 21: 904-19.
101. Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 causedominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011; 477: 211-5.
102. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Znsuperoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
103. Valentine JS, Hart PJ. Misfolded CuZnSOD and amyotrophiclateral sclerosis. Proc Natl Acad Sci USA 2003; 100: 3617-22.
104. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10: 524-30.
105. Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation ofhigh molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97: 12571-6.
106. Urushitani M, Kurisu J, Tateno M, et al. CHIP promotesproteasomal degradation of familial ALS-linked mutant SOD1 by ubiquitinating Hsp/Hsc70. J Neurochem 2004; 90: 231-44.
107. Farr GW, Ying Z, Fenton WA, Horwich AL. Hydrogen-deuteriumexchange in vivo to measure turnover of an ALS-associated mutant SOD1 protein in spinal cord of mice. Protein Sci 2011; 20: 1692-6.
108. Wang J, Farr GW, Zeiss CJ, et al. Progressive aggregation despitechaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc Natl Acad Sci USA 2009; 106: 1392-7.
109. Urushitani M, Kurisu J, Tsukita K, Takahashi R. Proteasomalinhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem 2002; 83: 1030-42.
110. Tummala H, Jung C, Tiwari A, Higgins CM, Hayward LJ, Xu Z. Inhibition of chaperone activity is a shared property of several Cu,Zn-superoxide dismutase mutants that cause amyotrophic lateral sclerosis. J Biol Chem 2005; 280: 17725-31.
111. Ishigaki S, Niwa J, Ando Y, et al. Differentially expressed genes insporadic amyotrophic lateral sclerosis spinal cords--screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett 2002; 531: 354-8.
112. Nishitoh H, Kadowaki H, Nagai A, et al. ALS-linked mutant SOD1induces ER stress-and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 2008; 22: 1451-64.
113. Tan JM, Wong ES, Kirkpatrick DS, et al. Lysine 63-linkedubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet 2008; 17: 431-9.
114. Hishikawa N, Niwa J, Doyu M, et al. Dorfin localizes to theubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. Am J Pathol 2003; 163: 609-19.
115. Niwa J, Ishigaki S, Hishikawa N, et al. Dorfin ubiquitylates mutantSOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem 2002; 277: 36793-8.
116. Ying Z, Wang H, Fan H, et al. Gp78, an ER associated E3,promotes SOD1 and ataxin-3 degradation. Hum Mol Genet 2009; 18: 4268-81.
117. Miyazaki K, Fujita T, Ozaki T, et al. NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J Biol Chem 2004; 279: 11327-35.
118. Choi JS, Cho S, Park SG, Park BC, Lee DH. Co-chaperone CHIPassociates with mutant Cu/Zn-superoxide dismutase proteins linked to familial amyotrophic lateral sclerosis and promotes their degradation by proteasomes. Biochem Biophys Res Commun 2004; 321: 574-83.
119. Yonashiro R, Sugiura A, Miyachi M, et al. Mitochondrial ubiquitinligase MITOL ubiquitinates mutant SOD1 and attenuates mutant SOD1-induced reactive oxygen species generation. Mol Biol Cell 2009; 20: 4524-30.
120. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencingreveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857-64.
121. Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familialand sporadic amyotrophic lateral sclerosis. Arch Neurol 2011; 68: 1440-6.
122. Ishigaki S, Hishikawa N, Niwa J, et al. Physical and functionalinteraction between Dorfin and Valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders. J Biol Chem 2004; 279: 51376-85.
123. Gal J, Strom AL, Kwinter DM, et al. Sequestosome 1/p62 linksfamilial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism. J Neurochem 2009; 111: 1062-73.
124. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxi-cation in humans and animals. Neuropathol 2000; 20 Suppl: S20-4.
125. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 2000; 173: 40-4.
126. Mao X, Li X, Sprangers R, et al. Clioquinol inhibits theproteasome and displays preclinical activity in leukemia and myeloma. Leukemia 2009; 23: 585-90.
127. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 2005; 7: R897-908.
128. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with acopper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76.
129. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-proteinattenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase2 clinical trial. Arch Neurol 2003; 60: 1685-91.
130. Hegde AN, DiAntonio A. Ubiquitin and the synapse. Nat RevNeurosci, 2002; 3: 854-61.
131. Lam YA, Xu W, DeMartino GN, Cohen RE. Editing of ubiquitinconjugates by an isopeptidase in the 26S proteasome. Nature 1997; 385: 737-40.
132. Zhang J, Hattori N, Leroy E, et al. Association between apolymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat Disord 2000; 6: 195-197.
133. Wilson SM, Bhattacharyya B, Rachel RA, et al. Synaptic defects inataxia mice result from a mutation in Usp14, encoding a ubiquitin specific protease. Nat Genet 2002; 32: 420-5.
134. Anderson C, Crimmins S, Wilson JA, Korbel GA, Ploegh HL, Wilson SM. Loss of Usp14 results in reduced levels of ubiquitin inataxia mice. J Neurochem 2005; 95: 724-31.
135. Koharudin LM, Liu H, Di Maio R, Kodali RB, Graham SH, Gronenborn AM. Cyclopentenone prostaglandin-induced unfoldingand aggregation of the Parkinson disease-associated UCH-L1. Proc Natl Acad Sci USA 2010; 107: 6835-40.
136. Li Z, Melandri F, Berdo I, et al. Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-proteinaggregation without proteasome inhibition. Biochem Biophys Res Commun 2004; 319: 1171-80.
137. Liu Y, Lashuel HA, Choi S, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cellline. Chem Biol 2003; 10: 837-46.
138. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010; 467: 179-84.